开发基于线粒体灾难相关基因的结肠腺癌的预后和化疗评估模型
Yinglei Liu1,2, Yamin Zhao1,3, Siming Zhang1
1Nantong Tumor Hospital and Affiliated Tumor Hospital of Nantong University, Nantong, China.
Scientific reports
|January 18, 2024
概括
线性灾难相关基因 (MCRG) 对结肠腺癌 (COAD) 预后至关重要. 一个5基因签名预测患者的生存和对治疗的反应,提供新的治疗点.
科学领域:
- 在瘤学瘤学.
- 细胞死亡研究 细胞死亡研究
- 基因组学就是基因组学.
背景情况:
- 线性灾难 (MC) 是细胞死亡途径,在结肠腺癌 (COAD) 治疗和耐药性方面具有重要意义.
- 了解MC相关基因对于COAD预后和治疗策略至关重要,但仍未得到充分探索.
研究的目的:
- 在结肠腺癌中识别和分析线粒体灾难相关基因 (MCRGs).
- 根据MCRG开发预后模型并探索基于MCRG的治疗目标.
主要方法:
- 利用TCGA数据进行转录组,突变和副本数变异.
- 执行差异基因表达,单变Cox回归和LASSO回归用于预后模型构建.
- 进行功能丰富,免疫透,瘤突变负担和药物敏感性分析.
主要成果:
- 确定了207种不同表达的MCRG,其中23种与COAD的整体存活 (OS) 有显著联系.
- 开发了一种5个枢纽的MCRG预后模型 (SYCE2,SERPINE1,TRIP6,LIMK1,EEPD1),其中高风险与预后较差相关.
- 创建了一个整合临床因素和风险评分的诺姆图,用于准确的生存预测;将MCRG与免疫微环境和化疗反应联系起来.
结论:
- 五枢纽的MCRG签名作为COAD的可靠预后生物标志物.
- 这些MCRG代表了COAD患者个性化治疗策略的潜在治疗目标.
相关概念视频
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
01:21Cancer Survival Analysis
353
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
353